28 results
8-K
EX-99.1
VRCA
Verrica Pharmaceuticals Inc
28 May 21
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
7:58am
, including its training program and distribution model, in response to comments from the agency regarding the Company’s human factors study. On May 26
8-K
VRCA
Verrica Pharmaceuticals Inc
23 Jul 20
Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes
7:45am
, was a pediatric resident and chief resident at Children’s Hospital of Philadelphia, and completed dermatology training at the hospital
8-K
EX-99.1
VRCA
Verrica Pharmaceuticals Inc
10 Aug 21
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
8:01am
to September 23, 2021 to allow the Agency additional time to review information requested and submitted regarding the Company’s training program
8-K
EX-99.2
VRCA
Verrica Pharmaceuticals Inc
24 Jul 23
Regulation FD Disclosure
7:31am
instructions and training prior to preparation and administration of YCANTH For topical use only. Not for Oral, mucosal, or ophthalmic use Apply a single
8-K
EX-99.2
VRCA
Verrica Pharmaceuticals Inc
18 Oct 19
Verrica Pharmaceuticals Announces Presentation of Positive Data
7:08am
Professor at the University of Vermont College of Medicine Janice Pelletier, MD Director of the residency training program and professor at UNC Dean
8-K
EX-99.1
19tnz
17 Apr 20
Regulation FD Disclosure
8:01am
8-K
EX-99.1
xf8baq71jlc5d
27 Jul 23
Regulation FD Disclosure
4:15pm
8-K
EX-99.1
rs5os6aovfa0kgc1f
8 Jan 24
Regulation FD Disclosure
8:01am
S-1
EX-10.17
f3kfo3
22 May 18
IPO registration
4:04pm
DRS/A
EX-10.17
i4f49mpvcepful
2 May 18
Draft registration statement (amended)
12:00am
DEF 14A
l1lvv lpvuhx
25 Apr 19
Definitive proxy
8:51am